mechanisms, tend to run in families, or to be identical in identical twins, or more similar in relatives than in strangers, is a non-problem or tautology which we could expect with sufficient assurance to be absolved from the need to document, and familial studies are only of value in the elucidation of heterogeneity.
We must, I think, regard the inborn variability of man as one of the facts of life. In an imaginary and uninhabitable world where the entire national budget was devoted to health we might test each patient for a therapeutic response and provide specific therapy in the same way as the blood banks provide labelled bottles matched to the recipient, but in practice this is a little unrealistic and we will usually be obliged to hope that most people respond in an average manner and provide documentation for any peculiarities or catastrophes which arise so that these may be studied later. In this context it is little short of criminal irresponsibility that a vast commercial framework exists for providing very large numbers of chemically similar drugs for the same purpose. There is no reason to suppose that the interaction of primary and secondary effects of very similar drugs will be similar and if these occasional and tragic side-effects are to be studied, predicted and eventually reduced, the first essential is that the number of drugs in use should be severely limited. Animal experimentation can only provide limited help since we have different metabolic maps, otherwise we would not be different species. Secondly, when untoward effects occur we should anticipate that this is likely to be due to a genetic weakness, in which case it is most likely to be recessively determined, and the patient should not only be warned about this particular drug and class of drug, but also asked to inform his sibs and to obtain the names of their doctors so that, if possible, similar risks need not be taken.
In conclusion, I would like to point out the possibility that fatal responses to drugs may be far commoner than is usually supposed. My reasoning for this is that in responsible medical circles, that is, the only circles whibchare likely to notice anything very amiss happening, powerful drugs are not normally used except in the presence of very serious disease so that, if anything unexpected happens, it is very difficult to determine whether this is due to the therapy or the disease. If, for example, the response to morphia or digitalis (to take two drugs within the monthly repertoire of most physicians) were to lead to death in 1 % of cases nothing much would have been noticed. The contraceptive pill would hardly have been suspect as a cause of thrombosis if it had been used to suppress lactation, or to improve wound healing, and we are now faced with the paradox that possibly the safest effective drug in use is the cause of greatest public anxiety. Perhaps the only reason why suxamethonium sensitivity has been noticed is that it occurs in the presence of observers who are looking for respiratory failure and equipped to compensate for it. Fortunately, the potentiality of linked records, and the costing of all ECIO prescriptions, will permit the automatic follow up of large populations as soon as the ECIO prescriptions are costed by computer, and allow us to learn from that small and irresponsible minority of our colleagues who, by responding obediently to advertising, impose on their patients hazards whose consequences they are ill fitted to observe and ill equipped to record. I believe this is one of the limited number of contributions a computer can make to medicine, and consider a unit for this purpose should be established in some well-automated region as a matter of urgency.
Dr Anth W Peck (Middlesex Hospital Medical School, London) Aspects of Suthonium Hydrolysis in Man an Animals Suxamethonium is the dicholine ester of succinic acid and a neuromuscular blocking drug with a very short duration of action, due to hydrolysis to succinylmonocholine by acylcholine acylhydrolase (cholinesterase, ChE), which is also known as pseudocholinesterase or butyrylcholinesterase. Following the introduction of suxamethonium into ansesthetic practice in the early 1950s occasional cases were seen in which the drug produced apncea lasting one hour or longer, instead of the usual two to three minutes. Cholinesterase activity in these cases, measured with acetylcholine (ACh) or benzoylcholine (BeCh) as substrate, was sometimes reduced but sometimes normal (Argent et al. 1955). Kalow & Genest (1957) demonstrated that a proportion of cases showing prolonged apncea had a qualitatively different form of ChE, which they called atypical ChE, in their plasma. Subsequently Kalow (1959) showed that by comparison with usual ChE the atypical ChE has a low affinity for suxamethonium and hence hydrolyses the ester extremely slowly. The atypical ChE, relative to usual ChE, also has a low affinity for positively charged inhibitors such as dibucaine and decamethonium. Inhibition of the enzymic hydrolysis of benzoylcholine by dibucaine was used by Kalow (1962) Kalow & Staron (1957) showed that the distribution of the DNs was best explained by postulating the presence of a pair of allelic genes inducing the synthesis of usual or atypical ChE. Subjects in the usual and atypical groups were regarded as homozygous for usual and atypical genes, respectively. Subjects in the intermediate group were regarded as heterozygous, with a plasma containing a mixture of the two forms of ChE. Members of the atypical group showed markedly prolonged apncea following suxamethonium, but in 1959 Kalow commented that only 10% of such cases belonged to the atypical group. Since that time evidence has accumulated for the existence of two other genes controlling the synthesis of ChE, the silent gene which fails to induce ChE (Liddell et al. 1962) , and the fluoride-resistant gene inducing a fluoride-resistant enzyme (Harris & Whittaker 1961) . Motulsky (1967) , reviewing 183 patients showing prolonged apnoea after suxamethonium, and including 78 cases initially studied by Thompson & Whittaker (1966) , found that there were still 35 % of such patients who had apparently usual ChE in their plasma, as assessed by DN and fluoride number (FN) values. Recently Whittaker (1968a, b) described variations in the extent of inhibition of ChE by sodium chloride and enhancement of its activity by butanol, suggesting possible new enzyme variants. The genetic control of these newer phenotypes is as yet unknown.
One of the difficulties in studies of the relationship between prolonged apncea and a given variant of ChE, particularly the newer ones, is the limitation of our knowledge on the hydrolysis of suxamethonium by the ChE variants. Hydrolysis of suxamethonium is difficult to study because it is hydrolysed by all forms of ChE at a much slower rate than BuCh (butyrylcholine), ACh, or BeCh. A method was therefore devised to study the enzymic hydrolysis of suxamethonium by different forms of ChE using a low substrate concentration similar to concentrations that might occur in vivo. Suxamethonium, 0-025 mM, was incubated with diluted plasma in phosphate buffer (pH 7 4) at 37°C, and hydrolysis of the ester was determined by testing aliquots of the incubation mixture on the isolated frog rectus abdominis muscle after various periods of incubation. For each plasma sample the hydrolysis of 10 mM BuCh and 0 05 mM BeCh were also determined manometrically and spectrophotometrically respectively. DNs and FNs were determined by the methods of Kalow & Genest (1957) , and Harris & Whittaker (1961), respectively.
Thirteen subjects belonging to the usual group, on the basis of DNs and FNs, had plasma activities of 395 ± 119 (SD) ,umoles BuCh/ml plasma per hour, and 4-4± 123 (SD) ,umoles suxamethonium/ml plasma per hour. Three subjects who developed prolonged apncea following suxamethonium administered during anesthesia had DNs of 21, 17, and 25, and family studies based on DNs suggested that each of them was homozygous for the atypical gene. The mean plasma activity of these three subjects was 156 pmoles BuCh/ml plasma per hour, and 0'028 ,moles suxamethonium/ml plasma per hour. A fourth subject, H Br, who presented with prolonged apnoea following suxamethonium, had a DN of 27 but was shown to be heterozygous for the usual and atypical genes. Studies of the inhibition by decamethonium of the enzymic hydrolysis of BuCh indicated that the plasma contained about 20% of ChE in the usual form. In addition, her daughter had plasma containing only usual ChE. Rates of hydrolysis of the two esters by the plasma of H Br were 156 pmoles BuCh/ml plasma per hour, and 0-46 pmoles suxamethonium/ml plasma per hour. The rate of hydrolysis of suxamethonium by this plasma, while only 10% of that for usual human plasma, was 16-fold greater than that by atypical human plasma. Plasma from a subject homozygous for the fluoride-resistant gene gave the following values: 334 ,umoles BuCh/ml plasma per hour and 1-58 ,umoles suxamethonium/ml plasma per hour. The ratio of suxamethonium hydrolysis to BuCh hydrolysis for the different human ChE variants expressed as a percentage was: usual ChE, 1 14±0-11 (SD); atypical ChE, 0-021; and fluoride-resistant ChE, 0-47.
To investigate the extent to which differences in rates of turnover of suxamethonium at the low substrate concentration used, 0-025 mM, might be attributable to differences in the degree of substrate saturation of the different forms of ChE, the inhibition of hydrolysis of 10 mM BuCh by different concentrations of suxamethonium was determined. The inhibition appeared to be competitive and from the concentration of suxamethonium required to produce 50% inhibition (150 value) and the Km value of BuCh, the apparent dissociation constant of suxamethonium, Ki, was calculated. The Ki value for atypical ChE was 60 times greater than that for usual ChE and this difference is sufficient to explain the discrepancy between the rates of hydrolysis of suxamethonium by the two enzymes.
It was concluded that the technique used for studying variants of human ChE would also be useful for investigating the hydrolysis of suxamethonium by the ChE of mammals generally used in model experiments concerning various aspects of the action of suxamethonium. Such studies are needed because the ease with which ChE in plasma can be studied has tended to overshadow the possible importance of ChE in the tissues and at the motor end-plate (Denz 1953 , Holmstedt 1957 , Haggqvist 1960 . The characteristics of plasma ChE in different species were therefore investigated and this was followed by studies of the relative importance of ChE in plasma and tissues in animals. Average values for rates of hydrolysis of BuCh and suxamethonium by plasmas from 12 cats and 7 dogs were: cat, 96-9±35-7 (SD) ,umoles BuCh/ml plasma per hour, and 0-101 +0-035 (SD) ,moles suxamethonium/ml plasma per hour; dog, 280+106 (SD) ,umoles BuCh/ml plasma per hour, and 0-239+ 0-088 (SD) jmoles suxamethonium/ml plasma per hour. Individual plasma samples from three varieties of monkey gave the following values: Cynomolgus, 826 pmoles BuCh/ml plasma per hour, 11-5 pmoles suxamethonium/ml plasma per hour; Rhesus, 611 pmoles BuCh/ml plasma per hour, 8-45 pmoles suxamethonium/ml plasma per hour; Patas (mean of two plasmas), 31-4 pmoles BuCh/ml plasma per hour, 0-295 pmoles suxamethonium/ml plasma per hour. In addition to variations in absolute rates of hydrolysis of suxamethonium, hydrolysis of suxamethonium relative to hydrolysis of BuCh varied widely between species. The values of the ratio suxamethonium hydrolysis/BuCh hydrolysis expressed as a percentage were: cat, 0-105±0-020 (SD); dog, 0-087+0-012 (SD); monkey (mean value), 1 20. The low relative turnover of suxamethonium by plasma from cat and dog means that any inference regarding hydrolysis of suxamethonium drawn from ChE activity measured with BuCh as substrate, will be grossly erroneous.
For the inhibition by suxamethonium of the hydrolysis of BuCh by ChE of different species the I" values were: cat, 0063 mM; dog, 1-8 mM; usual human, 2-3 mM; Cynomolgus monkey, 6-3 mM; Rhesus monkey, 4-8 mM; Patas, 3-5 mM. In spite of the low turnover of suxamethonium by cat ChE, the hydrolysis of BuCh by this enzyme was inhibited by much lower concentrations of suxamethonium than were required for inhibition of usual human ChE.
The Iso values for suxamethonium for cat and usual human ChE differed by a factor of 37. The Km values for the hydrolysis of BuCh by various ChEs were similar to that for usual human ChE, and the most likely explanation for the low turnover of suxamethonium by cat ChE is that the acylated enzyme formed by it has a much higher stability than that formed by usual human ChE. In suppoit of this interpretation is the finding that I50 values for inhibition of the two enzymes by decanethonium, which does not form an acylated enzyme, differ by a factor of only 3-5. The cat is 2 to 5 times more sensitive to suxa-methonium than is man, on a mg/kg basis, whereas the rate of hydrolysis of the ester by its plasma is only 2.5 % of that by usual human plasma. In addition, the cat has a shorter circulation time than man. Experiments, therefore, were performed in anesthetized cats for assessment of the relative importance of plasma and tissue ChE in the hydrolysis of suxamethonium. The effect of infusions of suxamethonium on responses of soleus and gastrocnemius muscles, stimulated via the sciatic nerve, was recorded. Raising the rate of hydrolysis of suxamethonium in plasma 16fold by administration of purified human ChE increased the infusion rate required to produce 50% paralysis only 1 3-fold for the soleus, and 1 A-fold for the gastrocnemius muscle. Thus a large increase in the ability of the plasma to hydrolyse suxamethonium in a cat with normal tissue ChE does not greatly affect the response to infused suxamethonium. The effects of reducing plasma ChE to 5% of the initial level by repeated withdrawal of blood into a syringe, incubation with diisopropyl phosphorofluoridate (DFP), and re-injection of the blood were also measured. Under these conditions DFP was hydrolysed by plasma phosphoryl phosphatase and tissue ChE activity, measured in the small intestine, fell by only 50% or less. In spite of the very large reduction in plasma ChE activity, the response to infused suxamethonium was only slightly increased. Marked inhibition of both plasma and tissue ChE, accomplished by the injection of tetra-isopropyl pyrophosphoramide (iso-OMPA), greatly reduced the rate of hydrolysis ofsuxamethonium by plasma and tissues, and the animals became 5-to 10-fold more sensitive to intravenous infusions of suxamethonium.
Detailed accounts of the studies summarized here, except the in vivo studies in cats, have been published elsewhere (Hobbiger & Peck 1969 , Peclc 1969 . Acknowledgments: The original work described in this paper was carried out in collaboration with Professor F Hobbiger to whom I am indebted, and formed part of a PhD thesis accepted by the University of London in December 1967. I am also grateful to Dr 0 P Dinnick and Dr H Lehmann for some of the human sera.
